Jyong Biotech Ltd.

EDGAR

Market value is not computed: this company’s US price is per depositary share, not per ordinary share.

5 filing records in this dataset, filed from 2023-08-17 to 2026-05-15. Reported financial figures are available; chart coverage varies by period.

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

This issuer has insider filings in the store, but no transaction in this window or code group.

5% holders (Schedule 13D and 13G)

  • Perfect Minds Co., Ltd 33.34% SCHEDULE 13D 06/16/2025
  • Innovation Global Group Limited 33.34% SCHEDULE 13D 06/16/2025
  • Unity Trust Limited as trustee of The Innovation Trust 33.34% SCHEDULE 13D 06/16/2025

See all insider transactions

Cash and cash equivalents
Not available
Long-term debt including current maturities
2.12 million USD
Exact inputs and evidence

2124000 USD

  • Long-term debt including current maturities: 2124000 USD Source
Shares outstanding
76 million shares Source
Exact value

76028000 shares

Reported share-count change

3.64% · 2.67 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence
  • 73361000 shares · 2024-12-31· Source
  • 76028000 shares · 2025-12-31· Source

Company performance

Up to ten complete financial years · consolidated figures

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-05-15.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • revenue: No compatible figures in this window
  • Operating income: 3 of 11 periods available· newest 2025-12-31
  • Net income: 3 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 3 of 11 periods available· newest 2025-12-31
  • capital expenditure: No compatible figures in this window
  • Total assets: 2 of 11 periods available· newest 2025-12-31
  • Total liabilities: 2 of 11 periods available· newest 2025-12-31
  • Current assets: 2 of 11 periods available· newest 2025-12-31
  • Current liabilities: 2 of 11 periods available· newest 2025-12-31
  • cash and cash equivalents: No compatible figures in this window
  • Long-term debt including current maturities: 1 of 11 periods available· newest 2025-12-31
  • Shares outstanding: 2 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    −USD 1.65 million

    Prior period

    −USD 3.02 million

    –

    Current period

    −USD 4.67 million

    –

    Exact inputs and evidence

    -4671000 − -3019000 = -1652000 USD

    -3019000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -4671000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    +USD 583,000

    Prior period

    −USD 3.62 million

    –

    Current period

    −USD 3.04 million

    –

    Exact inputs and evidence

    -3041000 − -3624000 = 583000 USD

    -3624000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -3041000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.
Values and sources
Revenue values and source evidence
PeriodSeriesValueSource evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValueSource evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2023 2023-01-01 – 2023-12-31
−USD 4.4 million
Exact value

Exact value: -4400000 USD

2023-01-01 – 2023-12-31: -4400000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 2.6 million
Exact value

Exact value: -2601000 USD

2023-01-01 – 2023-12-31: -2601000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2024 2024-01-01 – 2024-12-31
−USD 3.02 million
Exact value

Exact value: -3019000 USD

2024-01-01 – 2024-12-31: -3019000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 3.62 million
Exact value

Exact value: -3624000 USD

2024-01-01 – 2024-12-31: -3624000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2025 2025-01-01 – 2025-12-31
−USD 4.67 million
Exact value

Exact value: -4671000 USD

2025-01-01 – 2025-12-31: -4671000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 3.04 million
Exact value

Exact value: -3041000 USD

2025-01-01 – 2025-12-31: -3041000 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

5 filings · 116 latest values · 116 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001954488, 1954488, MENS, edgar:1954488

Also known as Jyong Biotech Ltd.